Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Abbott Laboratories, short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Turnover Ratios
Inventory turnover 2.74 2.71 2.62 2.77 3.10 3.37 3.24 3.36 3.59 3.47 3.27 2.99 2.99 2.71 2.56 2.92 3.07
Receivables turnover 6.11 6.15 6.52 6.89 7.02 7.03 6.33 6.20 6.64 6.61 6.58 6.13 5.40 5.70 6.12 6.06 5.88
Payables turnover 4.19 4.55 4.28 4.44 4.15 4.67 4.25 4.02 4.21 4.55 4.43 3.97 3.80 4.37 4.00 4.20 4.07
Working capital turnover 4.54 4.15 4.39 4.21 4.48 3.92 3.63 4.13 3.87 3.98 4.02 3.99 4.06 4.52 5.02 6.84 6.64
Average No. Days
Average inventory processing period 133 135 139 132 118 108 113 109 102 105 111 122 122 135 142 125 119
Add: Average receivable collection period 60 59 56 53 52 52 58 59 55 55 55 60 68 64 60 60 62
Operating cycle 193 194 195 185 170 160 171 168 157 160 166 182 190 199 202 185 181
Less: Average payables payment period 87 80 85 82 88 78 86 91 87 80 82 92 96 83 91 87 90
Cash conversion cycle 106 114 110 103 82 82 85 77 70 80 84 90 94 116 111 98 91

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Abbott Laboratories inventory turnover ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Receivables turnover An activity ratio equal to revenue divided by receivables. Abbott Laboratories receivables turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Abbott Laboratories payables turnover ratio increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Working capital turnover An activity ratio calculated as revenue divided by working capital. Abbott Laboratories working capital turnover ratio deteriorated from Q2 2023 to Q3 2023 but then improved from Q3 2023 to Q4 2023 exceeding Q2 2023 level.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Abbott Laboratories number of days of inventory outstanding improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Abbott Laboratories number of days of receivables outstanding deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Operating cycle Equal to average inventory processing period plus average receivables collection period. Abbott Laboratories operating cycle improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Abbott Laboratories number of days of payables outstanding decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Abbott Laboratories cash conversion cycle deteriorated from Q2 2023 to Q3 2023 but then improved from Q3 2023 to Q4 2023 exceeding Q2 2023 level.

Inventory Turnover

Abbott Laboratories, inventory turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cost of products sold, excluding amortization of intangible assets 4,556 4,605 4,483 4,331 4,593 4,629 4,933 4,987 4,766 4,423 4,947 4,401 4,493 3,966 3,263 3,281 3,434 3,358 3,279 3,160
Inventories 6,570 6,650 6,871 6,673 6,173 5,734 5,899 5,691 5,157 5,261 5,439 5,387 5,012 5,152 5,202 4,568 4,316 4,392 4,352 4,085
Short-term Activity Ratio
Inventory turnover1 2.74 2.71 2.62 2.77 3.10 3.37 3.24 3.36 3.59 3.47 3.27 2.99 2.99 2.71 2.56 2.92 3.07
Benchmarks
Inventory Turnover, Competitors2
Cigna Group 23.70 29.58 28.53 30.04 26.13 30.87 32.34 34.32 31.58 37.54 36.13 36.50 32.70 37.84 36.30 38.13 36.70
CVS Health Corp. 16.83 16.34 16.48 15.15 14.05 14.46 14.64 13.60 13.52 13.49 13.48 12.57 11.88 12.43 13.03 12.68 12.06
Danaher Corp. 3.80 4.04 3.90 3.65 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28 3.79 3.26 3.09 4.87
Intuitive Surgical Inc. 1.96 1.99 2.21 2.25 2.27 2.36 2.62 2.82 2.98 2.90 2.84 2.64 2.49 2.18 2.22 2.30 2.30
Medtronic PLC 2.03 1.92 2.00 2.09 2.20 2.26 2.38 2.47 2.43 2.24 2.20 2.10 2.23 2.34 2.35 2.37 2.44 2.35 2.39 2.42

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Inventory turnover = (Cost of products sold, excluding amortization of intangible assetsQ4 2023 + Cost of products sold, excluding amortization of intangible assetsQ3 2023 + Cost of products sold, excluding amortization of intangible assetsQ2 2023 + Cost of products sold, excluding amortization of intangible assetsQ1 2023) ÷ Inventories
= (4,556 + 4,605 + 4,483 + 4,331) ÷ 6,570 = 2.74

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Abbott Laboratories inventory turnover ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Receivables Turnover

Abbott Laboratories, receivables turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Net sales 10,241 10,143 9,978 9,747 10,091 10,410 11,257 11,895 11,468 10,928 10,223 10,456 10,701 8,853 7,328 7,726 8,314 8,076 7,979 7,535
Trade receivables, less allowances 6,565 6,499 6,172 6,020 6,218 6,408 7,199 7,179 6,487 6,405 6,113 6,096 6,414 5,649 5,140 5,292 5,425 5,450 5,548 5,345
Short-term Activity Ratio
Receivables turnover1 6.11 6.15 6.52 6.89 7.02 7.03 6.33 6.20 6.64 6.61 6.58 6.13 5.40 5.70 6.12 6.06 5.88
Benchmarks
Receivables Turnover, Competitors2
CVS Health Corp. 10.12 10.53 11.44 11.65 11.79 11.94 11.27 11.30 11.91 11.23 11.48 11.32 12.32 11.14 11.68 11.33 13.04
Danaher Corp. 6.09 7.04 7.23 7.18 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51 5.83 5.59 5.25 5.61
Elevance Health Inc. 18.08 17.93 18.82 16.53 18.81 19.51 18.80 16.67 20.66 18.93 18.81 17.39 19.72 18.91 18.04 16.74 18.20
Humana Inc. 51.75 55.60 68.53 30.60 55.25 56.74 26.54 27.18 45.69 42.91 32.51 35.43 66.78 64.58 31.30 33.43 60.97
Intuitive Surgical Inc. 6.30 7.12 7.37 6.95 6.60 7.20 7.11 6.52 7.30 7.90 7.38 6.96 6.75 7.32 8.56 8.73 6.94
Medtronic PLC 5.21 5.23 5.48 5.85 5.71 5.84 5.79 5.82 5.51 5.35 5.21 5.73 6.22 4.97 5.05 5.20 4.91 5.22 5.29 5.28
UnitedHealth Group Inc. 17.27 17.23 19.23 14.88 18.22 18.37 16.27 15.65 20.07 19.60 18.53 16.35 19.86 20.63 19.62 16.73 20.32

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Receivables turnover = (Net salesQ4 2023 + Net salesQ3 2023 + Net salesQ2 2023 + Net salesQ1 2023) ÷ Trade receivables, less allowances
= (10,241 + 10,143 + 9,978 + 9,747) ÷ 6,565 = 6.11

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Receivables turnover An activity ratio equal to revenue divided by receivables. Abbott Laboratories receivables turnover ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Payables Turnover

Abbott Laboratories, payables turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Cost of products sold, excluding amortization of intangible assets 4,556 4,605 4,483 4,331 4,593 4,629 4,933 4,987 4,766 4,423 4,947 4,401 4,493 3,966 3,263 3,281 3,434 3,358 3,279 3,160
Trade accounts payable 4,295 3,961 4,211 4,167 4,607 4,133 4,493 4,757 4,408 4,017 4,017 4,066 3,946 3,189 3,335 3,181 3,252 3,029 3,222 3,045
Short-term Activity Ratio
Payables turnover1 4.19 4.55 4.28 4.44 4.15 4.67 4.25 4.02 4.21 4.55 4.43 3.97 3.80 4.37 4.00 4.20 4.07
Benchmarks
Payables Turnover, Competitors2
Cigna Group 6.75 6.76 6.92 7.18 7.31 7.44 7.44 7.89 7.68 7.71 7.60 7.74 7.75 8.02 8.30 9.06 9.34
CVS Health Corp. 20.36 19.73 21.32 22.08 18.07 18.75 19.22 19.38 19.14 18.49 20.72 20.50 19.72 18.61 21.70 21.06 20.13
Danaher Corp. 5.58 6.45 6.35 5.93 5.45 5.61 5.00 5.04 4.48 5.20 5.54 5.29 4.79 5.46 5.28 4.55 5.23
Elevance Health Inc. 7.72 7.61 7.54 7.57 7.47 7.48 7.35 7.28 7.59 7.31 7.30 7.31 7.75 8.32 8.42 8.48 9.25
Humana Inc. 8.63 8.26 7.84 7.78 8.17 8.07 7.61 7.63 8.35 7.76 7.81 7.32 7.57 7.20 7.12 7.90 8.97
Intuitive Surgical Inc. 12.69 11.66 11.10 12.99 13.78 12.01 12.68 14.36 14.45 14.13 13.71 14.80 18.35 12.46 13.18 10.69 11.08
Medtronic PLC 4.03 4.68 4.60 4.62 4.46 5.14 5.41 5.67 4.98 5.56 5.19 5.56 4.72 4.96 4.84 4.89 4.69 5.31 5.16 4.98
UnitedHealth Group Inc. 7.47 7.11 7.08 6.86 7.26 7.07 6.90 6.78 7.63 6.98 6.97 6.58 7.29 7.40 8.02 6.96 7.21

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Payables turnover = (Cost of products sold, excluding amortization of intangible assetsQ4 2023 + Cost of products sold, excluding amortization of intangible assetsQ3 2023 + Cost of products sold, excluding amortization of intangible assetsQ2 2023 + Cost of products sold, excluding amortization of intangible assetsQ1 2023) ÷ Trade accounts payable
= (4,556 + 4,605 + 4,483 + 4,331) ÷ 4,295 = 4.19

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Abbott Laboratories payables turnover ratio increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.

Working Capital Turnover

Abbott Laboratories, working capital turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data (US$ in millions)
Current assets 22,670 22,664 23,505 24,377 25,224 24,845 24,956 23,429 24,239 23,492 22,627 21,817 20,441 17,390 17,221 15,498 15,667 16,119 15,195 14,409
Less: Current liabilities 13,841 13,042 14,350 14,530 15,489 13,365 12,392 12,647 13,105 12,867 12,614 12,462 11,907 10,257 10,959 10,808 10,863 10,491 9,062 9,113
Working capital 8,829 9,622 9,155 9,847 9,735 11,480 12,564 10,782 11,134 10,625 10,013 9,355 8,534 7,133 6,262 4,690 4,804 5,628 6,133 5,296
 
Net sales 10,241 10,143 9,978 9,747 10,091 10,410 11,257 11,895 11,468 10,928 10,223 10,456 10,701 8,853 7,328 7,726 8,314 8,076 7,979 7,535
Short-term Activity Ratio
Working capital turnover1 4.54 4.15 4.39 4.21 4.48 3.92 3.63 4.13 3.87 3.98 4.02 3.99 4.06 4.52 5.02 6.84 6.64
Benchmarks
Working Capital Turnover, Competitors2
Cigna Group
CVS Health Corp.
Danaher Corp. 4.22 2.50 3.35 3.97 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48 3.14 2.80 6.74 0.87
Elevance Health Inc. 7.83 7.92 7.69 7.60 8.37 9.11 8.85 8.65 7.23 6.79 6.67 5.38 6.39 5.98 5.40 6.81 6.11
Humana Inc. 9.47 9.72 9.34 8.98 10.27 10.54 9.53 9.27 8.67 7.47 7.38 7.61 7.42 6.04 6.14 6.91 7.19
Intuitive Surgical Inc. 1.14 0.95 1.03 1.15 1.29 1.21 1.17 1.26 1.22 1.17 1.03 0.88 0.77 0.80 0.88 1.23 1.23
Medtronic PLC 2.47 2.81 2.82 3.84 2.97 2.21 2.13 2.15 2.15 2.02 2.00 2.44 2.48 2.03 2.13 2.16 2.26 2.54 2.30 2.24
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Working capital turnover = (Net salesQ4 2023 + Net salesQ3 2023 + Net salesQ2 2023 + Net salesQ1 2023) ÷ Working capital
= (10,241 + 10,143 + 9,978 + 9,747) ÷ 8,829 = 4.54

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Working capital turnover An activity ratio calculated as revenue divided by working capital. Abbott Laboratories working capital turnover ratio deteriorated from Q2 2023 to Q3 2023 but then improved from Q3 2023 to Q4 2023 exceeding Q2 2023 level.

Average Inventory Processing Period

Abbott Laboratories, average inventory processing period calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data
Inventory turnover 2.74 2.71 2.62 2.77 3.10 3.37 3.24 3.36 3.59 3.47 3.27 2.99 2.99 2.71 2.56 2.92 3.07
Short-term Activity Ratio (no. days)
Average inventory processing period1 133 135 139 132 118 108 113 109 102 105 111 122 122 135 142 125 119
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
Cigna Group 15 12 13 12 14 12 11 11 12 10 10 10 11 10 10 10 10
CVS Health Corp. 22 22 22 24 26 25 25 27 27 27 27 29 31 29 28 29 30
Danaher Corp. 96 90 94 100 91 96 98 94 88 90 85 84 85 96 112 118 75
Intuitive Surgical Inc. 186 183 166 162 161 155 139 130 122 126 129 138 147 167 164 159 159
Medtronic PLC 180 190 183 174 166 161 153 148 150 163 166 174 164 156 155 154 150 156 153 151

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 2.74 = 133

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Abbott Laboratories number of days of inventory outstanding improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Average Receivable Collection Period

Abbott Laboratories, average receivable collection period calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data
Receivables turnover 6.11 6.15 6.52 6.89 7.02 7.03 6.33 6.20 6.64 6.61 6.58 6.13 5.40 5.70 6.12 6.06 5.88
Short-term Activity Ratio (no. days)
Average receivable collection period1 60 59 56 53 52 52 58 59 55 55 55 60 68 64 60 60 62
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
CVS Health Corp. 36 35 32 31 31 31 32 32 31 32 32 32 30 33 31 32 28
Danaher Corp. 60 52 50 51 57 51 54 53 57 55 56 58 66 63 65 69 65
Elevance Health Inc. 20 20 19 22 19 19 19 22 18 19 19 21 19 19 20 22 20
Humana Inc. 7 7 5 12 7 6 14 13 8 9 11 10 5 6 12 11 6
Intuitive Surgical Inc. 58 51 50 53 55 51 51 56 50 46 49 52 54 50 43 42 53
Medtronic PLC 70 70 67 62 64 63 63 63 66 68 70 64 59 73 72 70 74 70 69 69
UnitedHealth Group Inc. 21 21 19 25 20 20 22 23 18 19 20 22 18 18 19 22 18

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.11 = 60

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average receivable collection period An activity ratio equal to the number of days in the period divided by receivables turnover. Abbott Laboratories number of days of receivables outstanding deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Operating Cycle

Abbott Laboratories, operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data
Average inventory processing period 133 135 139 132 118 108 113 109 102 105 111 122 122 135 142 125 119
Average receivable collection period 60 59 56 53 52 52 58 59 55 55 55 60 68 64 60 60 62
Short-term Activity Ratio
Operating cycle1 193 194 195 185 170 160 171 168 157 160 166 182 190 199 202 185 181
Benchmarks
Operating Cycle, Competitors2
CVS Health Corp. 58 57 54 55 57 56 57 59 58 59 59 61 61 62 59 61 58
Danaher Corp. 156 142 144 151 148 147 152 147 145 145 141 142 151 159 177 187 140
Intuitive Surgical Inc. 244 234 216 215 216 206 190 186 172 172 178 190 201 217 207 201 212
Medtronic PLC 250 260 250 236 230 224 216 211 216 231 236 238 223 229 227 224 224 226 222 220

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 133 + 60 = 193

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Operating cycle Equal to average inventory processing period plus average receivables collection period. Abbott Laboratories operating cycle improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Average Payables Payment Period

Abbott Laboratories, average payables payment period calculation (quarterly data)

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data
Payables turnover 4.19 4.55 4.28 4.44 4.15 4.67 4.25 4.02 4.21 4.55 4.43 3.97 3.80 4.37 4.00 4.20 4.07
Short-term Activity Ratio (no. days)
Average payables payment period1 87 80 85 82 88 78 86 91 87 80 82 92 96 83 91 87 90
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Cigna Group 54 54 53 51 50 49 49 46 48 47 48 47 47 46 44 40 39
CVS Health Corp. 18 19 17 17 20 19 19 19 19 20 18 18 19 20 17 17 18
Danaher Corp. 65 57 57 62 67 65 73 72 82 70 66 69 76 67 69 80 70
Elevance Health Inc. 47 48 48 48 49 49 50 50 48 50 50 50 47 44 43 43 39
Humana Inc. 42 44 47 47 45 45 48 48 44 47 47 50 48 51 51 46 41
Intuitive Surgical Inc. 29 31 33 28 26 30 29 25 25 26 27 25 20 29 28 34 33
Medtronic PLC 91 78 79 79 82 71 67 64 73 66 70 66 77 74 75 75 78 69 71 73
UnitedHealth Group Inc. 49 51 52 53 50 52 53 54 48 52 52 56 50 49 46 52 51

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 4.19 = 87

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Abbott Laboratories number of days of payables outstanding decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.

Cash Conversion Cycle

Abbott Laboratories, cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Selected Financial Data
Average inventory processing period 133 135 139 132 118 108 113 109 102 105 111 122 122 135 142 125 119
Average receivable collection period 60 59 56 53 52 52 58 59 55 55 55 60 68 64 60 60 62
Average payables payment period 87 80 85 82 88 78 86 91 87 80 82 92 96 83 91 87 90
Short-term Activity Ratio
Cash conversion cycle1 106 114 110 103 82 82 85 77 70 80 84 90 94 116 111 98 91
Benchmarks
Cash Conversion Cycle, Competitors2
CVS Health Corp. 40 38 37 38 37 37 38 40 39 39 41 43 42 42 42 44 40
Danaher Corp. 91 85 87 89 81 82 79 75 63 75 75 73 75 92 108 107 70
Intuitive Surgical Inc. 215 203 183 187 190 176 161 161 147 146 151 165 181 188 179 167 179
Medtronic PLC 159 182 171 157 148 153 149 147 143 165 166 172 146 155 152 149 146 157 151 147

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

1 Q4 2023 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 133 + 6087 = 106

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Cash conversion cycle A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. Abbott Laboratories cash conversion cycle deteriorated from Q2 2023 to Q3 2023 but then improved from Q3 2023 to Q4 2023 exceeding Q2 2023 level.